Nürnberger W, Kruck H, Mauz-Körholz C, Burdach S, Göbel U
Department for Pediatric Hematology and Oncology, Heinrich Heine University Medical Center, Düsseldorf, Germany.
Klin Padiatr. 1997 Jul-Aug;209(4):209-15. doi: 10.1055/s-2008-1043952.
Alterations of the coagulation system that may lead to coagulation activation and thrombosis are common sequelae after allogeneic bone marrow transplantation (BMT). We performed prophylactic anticoagulation by low dose heparin (50 units/kg/day) and substitution of antithrombin (AT) concentrate to sustain plasma levels above 90% of pooled normal human plasma. Conventional tests for plasmatic hemostasis and substitution of AT concentrate were recorded for 50 patients until day +50 after BMT. Incidence of sepsis, graft-versus-host-disease [GVHD], capillary leakage syndrome [CLS] and veno-occlusive disease of the liver [VOD] were investigated and compared with the results of patients without any of these complications. Patients with proven sepsis (n = 6) showed decreased activity of AT, and a prolonged activated partial thromboplastin time (aPTT), while fibrinogen levels were slightly increased. This constellation was interpreted as mild to moderate activation of the humoral coagulation cascade. Patients with VOD (n = 10) showed an increased consumption of AT concentrate at day +7 followed by a decrease of prothrombin time, of clotting factors II and VII, and a prolongation of aPTT at days +11 to +18 after BMT. This suggests, that activation of coagulation precedes decreased synthesis of coagulation factors. Patients with CLS (n = 15) or GVHD > or = II degree (n = 14) showed no major alterations of coagulation parameters. In conclusion, after BMT, two types of coagulopathy were observed: (i) an activation of the coagulation cascade (i.e. sepsis and VOD) which was followed by (ii) a diminished synthesis of coagulation factors (VOD). In order to perform timely therapeutic interventions in the coagulation system in patients with sepsis and/or VOD it appears to be important to assess the clinical value of parameters for early detection of coagulation activation as thrombin-AT complexes, D-dimers and F1 + 2 fragments.
异基因骨髓移植(BMT)后,可能导致凝血激活和血栓形成的凝血系统改变是常见的后遗症。我们通过低剂量肝素(50单位/千克/天)和补充抗凝血酶(AT)浓缩物进行预防性抗凝,以维持血浆水平高于正常混合人血浆的90%。记录了50例患者在BMT后至+50天的血浆止血常规检测和AT浓缩物补充情况。调查了败血症、移植物抗宿主病[GVHD]、毛细血管渗漏综合征[CLS]和肝静脉闭塞病[VOD]的发生率,并与无这些并发症的患者结果进行比较。确诊败血症的患者(n = 6)显示AT活性降低,活化部分凝血活酶时间(aPTT)延长,而纤维蛋白原水平略有升高。这种情况被解释为体液凝血级联的轻度至中度激活。VOD患者(n = )在BMT后第+7天显示AT浓缩物消耗增加,随后凝血酶原时间、凝血因子II和VII降低,在第+11天至+18天aPTT延长。这表明,凝血激活先于凝血因子合成减少。CLS患者(n = 15)或GVHD≥II度患者(n = 14)的凝血参数无重大改变。总之,BMT后观察到两种类型的凝血病:(i)凝血级联激活(即败血症和VOD),随后是(ii)凝血因子合成减少(VOD)。为了对败血症和/或VOD患者的凝血系统进行及时的治疗干预,评估凝血酶-AT复合物、D-二聚体和F1 + 2片段等早期检测凝血激活参数的临床价值似乎很重要。 (注:原文中“VOD患者(n = )”括号内数字缺失,已按原文格式保留此问题)